SQZ Biotechnologies Co
OTC:SQZB

Watchlist Manager
SQZ Biotechnologies Co Logo
SQZ Biotechnologies Co
OTC:SQZB
Watchlist
Price: 0.024 USD Market Closed
Market Cap: $707.8k

Operating Margin

-500.5%
Current
Declining
by 66.1%
vs 3-y average of -434.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-500.5%
=
Operating Income
$-60.7m
/
Revenue
$12.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-500.5%
=
Operating Income
$-60.7m
/
Revenue
$12.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
SQZ Biotechnologies Co
OTC:SQZB
708k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-500.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

SQZ Biotechnologies Co
Glance View

Market Cap
707.8k USD
Industry
Biotechnology

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2020-10-30. The firm is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in human papillomavirus (HPV) plus tumors. The company is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that is designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

SQZB Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-500.5%
=
Operating Income
$-60.7m
/
Revenue
$12.1m
What is SQZ Biotechnologies Co's current Operating Margin?

The current Operating Margin for SQZ Biotechnologies Co is -500.5%, which is below its 3-year median of -434.4%.

How has Operating Margin changed over time?

Over the last 2 years, SQZ Biotechnologies Co’s Operating Margin has decreased from -346.8% to -500.5%. During this period, it reached a low of -500.5% on Oct 30, 2023 and a high of -253.8% on Dec 31, 2021.

Back to Top